GlassScriptPhysician profile
Gabriella B Olson
NPI 1699723429
$2,101.68
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $689 · 2023: $71.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $71.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $71.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $283.32 | 2019-2020 | |
| Novo Nordisk INC | $239.40 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $222.45 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $188.92 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $169.87 | 2019-2020 | |
| Amarin Pharma, INC. | $143.79 | 2019-2020 | |
| Glaxosmithkline, LLC. | $133.11 | 2019-2023 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $121.46 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.75 | 2019 | |
| Lilly USA, LLC | $100.48 | 2019-2020 | |
| Allergan, INC. | $75.82 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.68 | 2019-2020 | |
| Abbott Laboratories | $50.09 | 2023 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $37.96 | 2019 | |
| Csl Behring | $23.61 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23.23 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.59 | 2019 | |
| Radius Health, INC. | $18.02 | 2019 | |
| Pharming Healthcare, INC. | $17.73 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.68 | 2020 | |
| Sunovion Pharmaceuticals INC. | $14.76 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.51 | 2020 | |
| Pfizer INC. | $11.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriella Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.